Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
Despite advances in understanding the molecular mechanisms of brain cancer, the outcome of patients with malignant gliomas treated according to the current standard of care remains poor. Novel therapies are needed, and immunotherapy has emerged with great promise. The diffuse infiltration of malignant gliomas is a major challenge to effective treatment; immunotherapy has the advantage of accessing the entire brain with specificity for tumor cells. Therapeutic immune approaches include cytokine therapy, passive immunotherapy, and active immunotherapy. Cytokine therapy involves the administration of immunomodulatory cytokines to activate the immune system. Active immunotherapy is the generation or augmentation of an immune response, typically by vaccination against tumor antigens. Passive immunotherapy connotes either adoptive therapy, in which tumor-specific immune cells are expanded ex vivo and reintroduced into the patient, or passive antibody-mediated therapy. In this article, the authors discuss the preclinical and clinical studies that have used passive antibody-mediated immunotherapy, otherwise known as serotherapy, for the treatment of malignant gliomas.
Mitra
Siddhartha
S
Department of Neurosurgery, Stanford University School of Medicine, 300 Pasteur Drive, Edwards Building Room 200, Stanford, CA 94305, USA.
Li
Gordon
G
Harsh
Griffith R
GR
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000628:therapy*; D066246:ErbB Receptors / Q000276:immunology; D016326:Extracellular Matrix Proteins / Q000276:immunology; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D016233:Immunotherapy, Active; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016326:Extracellular Matrix Proteins; D042461:Vascular Endothelial Growth Factor A; C410723:epidermal growth factor receptor VIII; D000068258:Bevacizumab; D066246:ErbB Receptors